Samsung aims to support your Ozempic weight loss journey with its smartwatch.

      Samsung is delving further into the Ozempic era with a study at Mass General aimed at determining if a smartwatch can help individuals comprehend the changes that occur after initiating GLP-1 treatment.

      This six-month study will concentrate on adults commencing GLP-1RA therapy, a class of drugs commonly linked to significant weight-loss outcomes. The research will not solely focus on weight loss but will also monitor muscle mass, activity levels, heart rate, and body composition throughout the treatment.

      Collaborating with Massachusetts General Hospital, Samsung is incorporating Galaxy Watch8 data into a clinical study centered on a rapidly advancing form of care. The objective is to assess whether data from the watch can provide valuable insights during GLP-1 treatment without classifying the device as a medical tool.

      Can a smartwatch capture what scales overlook?

      Researchers will evaluate two groups of adults who are starting GLP-1RA therapy. One cohort will utilize the Galaxy Watch8, which will track health metrics like body composition, activity data, heart rate monitoring, and personalized exercise recommendations through Samsung Health. The other group will receive standard care and guidance.

      Samsung

      To establish a more robust baseline for body composition than what the watch alone can offer, DXA scans will be employed. This ensures that the study remains anchored, given that Samsung’s body composition feature is designed as a wellness tool rather than a diagnostic device.

      The watch is not meant to substitute medical care. The researchers aim to determine whether daily data can bridge the gap between medical appointments, where observing changes in activity, weight, and body composition may be challenging.

      The need for more signals in GLP-1 care

      GLP-1 medications have transformed the weight-loss industry, but a bathroom scale provides a limited perspective. An individual can shed pounds while simultaneously losing muscle, altering activity habits, or requiring additional exercise assistance during treatment.

      Samsung is combining passive tracking with customized guidance to evaluate whether smartwatch data can aid individuals in their treatment. A more challenging aspect of the study is testing whether the collected signals are sufficiently valuable for both clinicians and patients to act upon.

      Andy Boxall / Digital Trends

      Currently, the value of this data is still under investigation. The study design places consumer wearable data alongside a more established method of measuring body composition, resulting in a more rigorous evaluation than activity tracking alone.

      Future directions for Samsung

      The next significant milestone is the six-month study duration. Should the findings demonstrate that Galaxy Watch8 data effectively tracks meaningful changes during GLP-1RA therapy, Samsung will gain further evidence supporting the connection between watch data and treatment assistance.

      There are still unanswered questions. Samsung has not disclosed the number of participants or the timeline for releasing results, meaning the practical implications remain unclear until the findings are published.

      Individuals starting GLP-1 treatment should consider Galaxy Watch data as supplementary information and keep medical decisions with a healthcare provider. For Samsung, the rise of Ozempic presents an important opportunity to validate its health ambitions.